Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Basilea Pharmaceutica Ltd. announces that it has received a milestone payment of EUR 5.5 million under its distribution agreement for Toctino® (alitretinoin) with Almirall, S.A. The milestone payment of EUR 5.5 million relates to Italy where Toctino® will become available in the coming weeks and local market access activities have been initiated in the individual regions throughout Italy.
Hand eczema is a common inflammatory skin disease and is often chronic and relapsing. Hand eczema is reported to affect up to ten percent of the general population. The more severe, chronic form of the condition is thought to affect five to seven percent of these patients, causing impaired use of their hands and a considerable impact on their ability to perform everyday activities. Toctino® (alitretinoin), the only therapy approved for severe chronic hand eczema unresponsive to potent topical treatments.
In Italy, Toctino® is approved for the use in adults who have severe chronic hand eczema (CHE) that is unresponsive to treatment with potent topical corticosteroids. Basilea is marketing Toctino® in France, Germany, the United Kingdom, Switzerland and Denmark and has appointed distributors for Toctino® in other selected European markets, Canada and Mexico.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
